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Mobile phone use and incidence of brain tumour histological types,
grading or anatomical location: A populationbased ecological study
Abstract
Objective Some studies have reported increasing trends in certain brain tumours and a possible link with
mobile phone use has been suggested. We examined the incidence time trends of brain tumour in Australia for
three distinct time periods to ascertain the influence of improved diagnostic technologies and increase in
mobile phone use on the incidence of brain tumours.
Design In a population-based ecological study, we examined trends of brain tumour over the periods 1982-
1992, 1993-2002 and 2003-2013. We further compared the observed incidence during the period of
substantial mobile phone use (2003-2013) with predicted (modelled) incidence for the same period by
applying various relative risks, latency periods and mobile phone use scenarios.
Setting National Australian incidence registration data on primary cancers of the brain diagnosed between
1982 and 2013.
Population 16 825 eligible brain cancer cases aged 20- 59 from all of Australia (10 083 males and 6742
females).
Main outcome measures Annual percentage change (APC) in brain tumour incidence based on Poisson
regression analysis.
Results The overall brain tumour rates remained stable during all three periods. There was an increase in
glioblastoma during 1993-2002 (APC 2.3, 95% CI 0.8 to 3.7) which was likely due to advances in the use of
MRI during that period. There were no increases in any brain tumour types, including glioma (-0.6, -1.4 to
0.2) and glioblastoma (0.8, -0.4 to 2.0), during the period of substantial mobile phone use from 2003 to 2013.
During that period, there was also no increase in glioma of the temporal lobe (0.5, -1.3 to 2.3), which is the
location most exposed when using a mobile phone. Predicted incidence rates were higher than the observed
rates for latency periods up to 15 years.
Conclusions In Australia, there has been no increase in any brain tumour histological type or glioma location
that can be attributed to mobile phones.
Disciplines
Medicine and Health Sciences
Publication Details
Karipidis, K., Elwood, M., Benke, G., Sanagou, M., Tjong, L. & Croft, R. J. (2018). Mobile phone use and
incidence of brain tumour histological types, grading or anatomical location: A populationbased ecological
study. BMJ Open, 8 (12), e024489-1-e024489-11.
Authors
Ken Karipidis, Mark Elwood, Geza P. Benke, Masoumeh Sanagou, Lydiawati Tjong, and Rodney J. Croft
This journal article is available at Research Online: https://ro.uow.edu.au/ihmri/1332
1Karipidis K, et al. BMJ Open 2018;8:e024489. doi:10.1136/bmjopen-2018-024489
Open access 
Mobile phone use and incidence of 
brain tumour histological types, grading 
or anatomical location: a population-
based ecological study
Ken Karipidis,1 Mark Elwood,2 Geza Benke,3 Masoumeh Sanagou,1 
Lydiawati Tjong,1 Rodney J Croft4
To cite: Karipidis K, Elwood M, 
Benke G, et al.  Mobile 
phone use and incidence 
of brain tumour histological 
types, grading or anatomical 
location: a population-based 
ecological study. BMJ Open 
2018;8:e024489. doi:10.1136/
bmjopen-2018-024489
 ► Prepublication history and 
additional material for this 
paper are available online. To 
view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2018- 
024489).
Received 30 May 2018
Revised 6 August 2018
Accepted 5 November 2018
1Australian Radiation Protection 
and Nuclear Safety Agency, 
Yallambie, Victoria, Australia
2School of Population Health, 
University of Auckland, 
Auckland, New Zealand
3School of Public Health and 
Preventive Medicine, Monash 
University, Melbourne, Victoria, 
Australia
4Australian Centre for 
Electromagnetic Bioeffects 
Research, Illawarra Health and 
Medical Research Institute, 
University of Wollongong, 
Wollongong, New South Wales, 
Australia
Correspondence to
Dr Ken Karipidis;  
 ken. karipidis@ arpansa. gov. au
Research
© Author(s) (or their 
employer(s)) 2018. Re-use 
permitted under CC BY-NC. No 
commercial re-use. See rights 
and permissions. Published by 
BMJ.
AbstrACt
Objective Some studies have reported increasing 
trends in certain brain tumours and a possible link with 
mobile phone use has been suggested. We examined the 
incidence time trends of brain tumour in Australia for three 
distinct time periods to ascertain the influence of improved 
diagnostic technologies and increase in mobile phone use 
on the incidence of brain tumours.
Design In a population-based ecological study, we 
examined trends of brain tumour over the periods 1982–
1992, 1993–2002 and 2003–2013. We further compared 
the observed incidence during the period of substantial 
mobile phone use (2003–2013) with predicted (modelled) 
incidence for the same period by applying various relative 
risks, latency periods and mobile phone use scenarios.
setting National Australian incidence registration data on 
primary cancers of the brain diagnosed between 1982 and 
2013.
Population 16 825 eligible brain cancer cases aged 20–
59 from all of Australia (10 083 males and 6742 females).
Main outcome measures Annual percentage change 
(APC) in brain tumour incidence based on Poisson 
regression analysis.
results The overall brain tumour rates remained 
stable during all three periods. There was an increase in 
glioblastoma during 1993–2002 (APC 2.3, 95% CI 0.8 
to 3.7) which was likely due to advances in the use of 
MRI during that period. There were no increases in any 
brain tumour types, including glioma (−0.6, –1.4 to 0.2) 
and glioblastoma (0.8, –0.4 to 2.0), during the period of 
substantial mobile phone use from 2003 to 2013. During 
that period, there was also no increase in glioma of the 
temporal lobe (0.5, –1.3 to 2.3), which is the location most 
exposed when using a mobile phone. Predicted incidence 
rates were higher than the observed rates for latency 
periods up to 15 years.
Conclusions In Australia, there has been no increase in 
any brain tumour histological type or glioma location that 
can be attributed to mobile phones.
IntrODuCtIOn 
Since its introduction in the mid-80s mobile 
phone use has grown rapidly worldwide. 
When using a mobile phone against the 
head, the brain is exposed to much higher 
levels of radiofrequency (RF) radiation than 
the rest of the body1 and there has been 
continuing concern of a possible association 
with brain cancer. Several case–control and 
registry-based cohort studies have found little 
evidence to support such an association.2 
However a few other case–control studies, 
most notably the Interphone study (2010) 
and a Swedish study by Hardell et al have 
reported modest to large associations with 
glioma, the most common type of primary 
brain tumour.3–5 These studies have gener-
ally found no association with other brain 
tumour types such as meningioma. Based on 
these results, the International Agency for 
Research on Cancer (IARC) has classified RF 
as ‘possibly carcinogenic to humans’.6
From a public health perspective, given that 
the great majority of the population regu-
larly uses mobile phones, even a relatively 
small excess risk would result in a significant 
number of additional brain tumour cases. In 
time, such an increase would be observable in 
cancer surveillance data sources.7 The World 
Health Organization (WHO) has previously 
identified as a high research priority the 
monitoring of brain tumour incidence trends 
through well-established population-based 
strengths and limitations of this study
 ► This study investigated incidence time trends for dif-
ferent brain tumour histological types, grading and 
anatomical location over different time periods.
 ► The study compared the observed brain tumour inci-
dence rates with modelled predicted incidence rates 
assuming a causal association with mobile phone 
use.
 ► Mobile phone subscription data and information 
from surveys may not accurately represent mobile 
phone use patterns in adults.
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cancer registries and combined with population exposure 
data.8
Since the WHO recommendation, a limited number 
of ecological studies have shown that although the preva-
lence of mobile phone use (usually measured through the 
number of mobile phone accounts) has seen a massive 
increase, the time trends of brain tumour incidence 
have remained fairly stable.9 10 Other studies have shown 
increases in certain brain tumour subtypes or specific 
anatomical locations.10 11 However, it has been suggested 
that the introduction of better diagnostic methods 
(CT and MRI) have improved the detection of brain 
cancers which leads to increased population incidence.12 
Further, a few recent studies, most notably in the USA 
and Australia, have shown that predicted incidence rates 
based on the associations reported by the Interphone and 
Hardell studies for ‘heavy’ mobile phone users are higher 
than the observed rates.13 14 Apart from the study by Little 
et al,13 previous results have generally failed to show the 
incidence trends for different brain tumour histological 
and topographical types.13 Further, the simulation of 
expected rates in these studies was only performed for 
a latency period of 10 years and if there is an association 
with mobile phone use the latency could be longer.
In this study, we analysed the incidence trends of brain 
tumour for three distinct time periods to ascertain the 
influence of improved diagnostic methods and increase 
in mobile phone use. The analysis considered different 
histological types and subtypes, glioma grades and glioma 
anatomical sites. We further compared the observed inci-
dence during the period of substantial mobile phone 
use (2003–2013) with predicted incidence for the same 
period based on relative risks (RRs) reported by the two 
epidemiological studies forming the basis of the IARC 
classification.3 4
MethODs
Collection of incidence data
Incidence data on primary cancers of the brain and 
central nervous system diagnosed between 1982 and 
2013 inclusive (the latest available) were obtained from 
the Australian Institute of Health and Welfare (AIHW). 
Reporting of incident invasive cancer is mandatory in all 
Australian states and territories and the AIHW has been 
collecting and reporting national data on brain cancer 
incidence since 1982. The data included information 
on primary anatomical site (International Classification 
of Diseases Version 10, ICD-10 topography codes, C70–
C72), histology, diagnosis year and diagnosis age (in 
5 year groups: 0–4, 5–9 … 80–84, 85+). Data were not 
available for one Australian state (New South Wales) for 
the year 2013.
Patient and public involvement
Patients or the public were not involved in this study.
statistical analysis of observed incidence
Based on the results of the Interphone study, we analysed 
intracranial brain cancer incidence in adults aged 20–59; 
neoplasms of the spinal cord, cranial nerves and other 
parts of central nervous system (ICD-10 code C72) were 
excluded. Annual age-standardised incidence rates per 
100 000 person-years were calculated separately for males, 
females and both genders by using WHO’s standard popu-
lation. Histology was analysed by categorising glioma, 
meningioma, other histological types and brain cancers 
with unspecified histology based on WHO’s Classification 
of tumours of the central nervous system.15 We further 
analysed glioma by categorising glioblastoma (which is 
the most common brain tumour subtype), glioma grade 
(low, high and unspecified) and glioma location (frontal 
lobe, temporal lobe, parietal lobe, other locations, over-
lapping lobes and unspecified). The categories analysed 
and their respective ICD-10 codes are shown in table 1.
A large number of tumours had unspecified classifi-
cations, particularly for glioma grade and glioma loca-
tion. We approximated the classification of unspecified 
tumours by recalculating the adjusted rates for each year 
by adding the unspecified group to the other groups in 
proportion to the distribution of specified tumours.
The incidence rates were low compared with the popu-
lation at risk so the variability in the observed cases was 
assumed to follow a Poisson distribution.16 Analyses of 
incidence time trends were carried out using Poisson 
regression to estimate the annual percentage change 
(APC) in the incidence, with corresponding 95% CI over 
three time periods: 1982–1992 (representing increased 
CT and MRI use), 1993–2002 (representing advances 
in MRI) and 2003–2013 (representing substantial and 
increasing mobile phone use; more than 65% of the 
population).17 Lowess smoothing was used in the graph-
ical representation of the time trends.
Table 1 International Classification of Diseases Version 10 
histology and topography codes
Histology
  Glioma 9380–9480
  Glioblastoma 9440–9442
  Meningioma 9530–9539
  Other 8010–9371, 9490–9508, 9540–9561
  Unspecified 8000–8004
Glioma grade
  Low (I and II) 9384, 9391, 9393, 9400, 9410, 9411, 9420, 
9421, 9424, 9425, 9450
  High (III and IV) 9381, 9392, 9401, 9440–9442, 9451, 
9470–9474, 9480
  Unspecified 9380, 9382, 9390, 9423, 9430, 9460
Topography
  Frontal C711
  Temporal C712
  Parietal C713
  Other locations C700, C701, C709, C710, C714–C717
  Overlapping C718
  Unspecified C719
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Mobile phone use data sources
Mobile phone use was estimated using information on 
mobile phone accounts and survey data on actual use. 
Data on the annual number of mobile phone accounts 
from 1987, when mobile telephony first commenced 
in Australia, to 2013 were obtained from the national 
telecommunications regulator, the Australian Commu-
nications and Media Authority (ACMA). The number 
of mobile phone accounts per capita for each year was 
calculated by dividing the number of accounts by the 
total Australian population in that year (obtained from 
the Australian Bureau of Statistics), noting that since 
2008 the annual number of accounts has been exceeding 
the number of people in the population. These data are 
not a true indication of mobile phone use as some users 
may have had more than one account and other users 
no account. A consumer survey conducted by ACMA 
reported that approximately 90% of the population used 
mobile phones in the years 2009 –2013.18 We estimated 
the annual prevalence of mobile phone use (shown in 
figure 1) by multiplying the annual number of accounts 
per capita by a factor of 0.9.18 It was not possible to stratify 
prevalence of use by age or gender; thus, an overall esti-
mate of prevalence is provided equally for all ages across 
the 20–59 age range and for both males and females.
statistical analysis of predicted incidence
With the assumption that mobile phone use is associ-
ated with glioma in adults as reported by the Interphone 
and Swedish studies, we calculated predicted incidence 
rates and time trends by applying various RRs (1.5, 2, 2.5, 
3) and latency periods (1, 5, 10, 15, 20 years) for three 
different mobile phone use scenarios:
a. All users—RRs were applied to all mobile phone users.
b. (Heavy users—RRs were applied to heavy mobile 
phone users (defined as 19% of mobile phone users by 
the Interphone study).
c. Regular users and heavy users—RR of 1.5 applied to 
regular users (81% of all users) and RRs of 2, 2.5 and 3 
applied to heavy users (19% of all users).
The annual predicted incidence rates were calculated 
for the period 1987–2013 using the formula:
Predicted incidence = (P×RR×IB) + ((1−P)×IB)
where P denotes the annual prevalence of mobile 
phone use, RR and IB the premobile phone baseline inci-
dence from 1982 to 1987. CIs and statistical significance 
of observed and expected incidence rates were calcu-
lated using Poisson CIs as described in Ulm.19 Analyses of 
predicted incidence time trends were carried out by esti-
mating the APC for the period 2003–2013, representing 
the time that mobile phone use increased rapidly.
We used Stata/SE V.15.0 for all analyses. The reporting 
of our study conforms to the Strengthening the Reporting 
of Observational Studies in Epidemiology statement.20
results
Observed incidence
There was a total of 16 825 eligible brain cancer cases 
aged 20–59 (10 083 males and 6742 females) that were 
diagnosed between 1982 and 2013. Of these 15 758 
(93.7%) were gliomas, 312 (1.9%) were meningiomas, 
Figure 1 Estimated percentage of Australian population using mobile phones.
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239 (1.4%) were other histological types and 516 (3.1%) 
were tumours of unspecified histology. The most common 
brain tumour subtype was glioblastoma (7326, 43.5%). Of 
the gliomas, 4699 (29.8%) were low grade, 9300 (59%) 
were high grade and 1759 (11.2%) were of unspecified 
grade. The most common glioma anatomical location was 
the frontal lobe (4422, 28.1%), followed by the temporal 
lobe (2952, 18.7%) and parietal lobe (2272, 14.4%). 
There were 2372 (15.1%) tumours in other locations, 
968 (6.1%) overlapping locations and 2772 (17.6%) with 
unspecified location.
The observed incidence rates between 1982 and 2013 
are shown in figure 2 for both genders and online supple-
mentary figure A for males and females separately. Further, 
the observed incidence trends (given as APC) over the 
time periods 1982–1992, 1993–2002 and 2003–2013 are 
shown in table 2 for both genders and online supple-
mentary table A for males and females separately. The 
overall brain tumour rates remained stable in all three 
time periods and the trends were similar for males and 
females. Glioblastoma increased during the period that 
saw advances in MRI (1993–2002) while it remained stable 
during the period of substantial mobile phone use (2003–
2013); this later period also saw a decrease in other glioma 
subtypes. The APC for glioblastoma in both genders for 
the entire observation period, that is, 1982–2013 (not 
shown in table 2) was 1.45 (1.11–1.79). There was a 
strong decreasing trend in brain tumours with unspec-
ified histology during the period of increased CT and 
MRI use (1982–1992). With the redistribution of unspec-
ified tumours, there were no significant changes to these 
histological trends (table 3 for both genders and online 
supplementary table B for males and females separately).
Looking at glioma grade in table 2, high-grade gliomas 
increased during both periods of improved diagnosis 
while low-grade gliomas decreased during the periods 
of advances in MRI (1993–2002) and substantial mobile 
phone use (2003–2013). There was a strong decreasing 
trend in gliomas with unspecified grade during the 
period of increased CT and MRI use (1982–1992). The 
redistribution of unspecified tumours did not change the 
glioma grade trends (table 3).
For glioma location in table 2, there were increasing 
trends for all locations and a strong decreasing trend for 
unspecified location during the period of increased CT 
and MRI use (1982–1992). There were also increases in 
the frontal and temporal lobes and a smaller decrease in 
unspecified location during the period of advances in MRI 
(1993–2002); this period also had a very large decrease in 
gliomas with overlapping location. During the period of 
substantial mobile use, there were no increases in any of 
the locations apart from the frontal lobe and there was a 
strong decrease in unspecified location. With the redistri-
bution of a high number of gliomas with unspecified and 
overlapping location, there was a much lower increasing 
trend only for gliomas in the frontal lobe during all three 
periods and a large increase in the parietal lobe during 
the first period (table 3).
Predicted incidence
Assuming a causal association between mobile phone 
use and glioma, the predicted incidence trends for both 
genders during 2003–2013 by applying various RRs, 
latency periods and mobile phone use scenarios are 
shown in table 4. The predicted incidence trends showed 
an increase for most mobile phone use scenarios and 
latency periods that were modelled apart from a 20-year 
latency period. There were also no statistically signif-
icant increases when applying the model to only heavy 
users for RRs less than 3. The highest expected trends 
were generally seen for a 10-year latency period, which 
was the latency period associated with mobile phones and 
brain tumour as reported in the Interphone and Swedish 
studies.
The observed and predicted glioma incidence rates for 
both genders from 1987 to 2013 are shown in figure 3 for 
a 10-year latency and online supplementary figure B for 1, 
5, 15 and 20 years latencies. With an RR of 2 for all mobile 
phone users and a latency of 10 years, the predicted inci-
dence rate for both genders in 2013 was 7.3 per 100 000 
people (95% CI 6.7 to 7.9) compared with the observed 
4.5 per 100 000. The predicted rates increase to 8.7 (95% 
CI 8.1 to 9.3) and 10.2 (95% CI 9.5 to 10.8) per 100 000 
for RRs of 2.5 and 3, respectively. With an RR of 1.5 for 
regular users and an RR of 2 for heavy users and a latency 
of 10 years the predicted rate was 6.1 per 100 000 (95% 
CI 5.6 to 6.6); increasing to 6.4 (95% CI 5.9 to 6.9) and 
6.7 (95% CI 6.1 to 7.2) when applying RRs of 2.5 and 3 to 
heavy users, respectively. Assuming a latency of 15 years, 
the predicted incidence rates in 2013 were also higher 
compared with the observed rate. The model did not 
show an increasing trend for a latency of 20 years.
DIsCussIOn
The results of our study showed that the overall brain 
tumour rates in adults aged 20–59 years showed no 
increasing or decreasing trend. This is in line with studies 
showing stable brain tumour trends in other coun-
tries.10–12 Furthermore, the trends in our study were stable 
for different histological types, like glioma, which has 
been reported in some case–control studies as being asso-
ciated with mobile phone use.3 4 The all glioma incidence 
rates were stable in both the periods before (1982–1992, 
1993–2002) and the period after (2003–2013) substan-
tial mobile phone use. For a causal relationship between 
mobile phone use and brain cancer, one would expect an 
increasing trend in the later period and no trend in the 
earlier periods.
There has been limited research showing the time 
trends of histological subtypes and particularly glioblas-
toma, which is the most common and most malignant 
brain tumour subtype in adults.5 Philips et al21 reported 
that the incidence of glioblastoma more than doubled 
in England between 1995 and 2015; however, the 
authors did not analyse different periods to investi-
gate the impact of mobile phone use.21 Dobes et al22 
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Figure 2 Observed incidence rates (smoothed*) in adults (both genders, 20–59 years old) during 1982–2013.
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reported an increasing trend in glioblastoma incidence 
in Australia between 2000 and 2008 in people aged 65 
years or older; noting that the cases were ascertained 
directly from neurological centres.22 Our study used all 
the national incident brain cancer registrations avail-
able through Australia’s high-quality state and territory 
Table 2 Observed age-standardised brain tumour incidence trends in adults (both genders, 20–59 years old) during increased 
CT and MRI use (1982–1992), advances in MRI use (1993–2002) and substantial mobile phone use (2003–2013)
1982–1992 1993–2002 2003–2013
N APC 95% CI N APC 95% CI N APC 95% CI
  All 4793 0.1 (−0.8 to 1) 5270 0.5 (−0.5 to 1.5) 6762 −0.8 (−1.6 to 0)
Histology
  Glioma 4347 1.1 (0.2 to 2.1) 4990 0.4 (−0.6 to 1.4) 6421 −0.6 (−1.4 to 0.2)
  Glioblastoma 1638 1.4 (−0.1 to 2.9) 2397 2.3 (0.8 to 3.7) 3291 0.8 (−0.4 to 2)
  Other glioma 2709 1 (−0.2 to 2.2) 2593 −1.2 (−2.6 to 0.1) 3130 −1.8 (−2.9 to 0.7)
  Meningioma 82 −0.4 (−6.9 to 6.6) 110 2.4 (−4.2 to 9.4) 120 −4.4 (−10.1 to 1.7)
  Other 79 −7.3 (−13.6 to 0.6) 66 −1.5 (−9.5 to 7.2) 94 −5.3 (−11.3 to 1)
  Unspecified 285 −13.4 (−16.6 to 10) 104 4.6 (−2.3 to 12) 127 −4.8 (−10.3 to 0.9)
Glioma grade
  Low 1817 1.1 (−0.4 to 2.6) 1418 −3.8 (−5.5 to 2) 1464 −3.1 (−4.7 to 1.5)
  High 1938 3.8 (2.3 to 5.2) 3151 2.1 (0.9 to 3.4) 4211 −0.1 (−1.1 to 1)
  Unspecified 592 −6.9 (−9.2 to 4.5) 421 2.2 (−1.2 to 5.7) 746 2 (−0.4 to 4.5)
Glioma location
  Frontal 933 7.8 (5.6 to 10.1) 1345 3.7 (1.8 to 5.7) 2144 3 (1.6 to 4.5)
  Temporal 599 7.3 (4.6 to 10.1) 982 2.8 (0.6 to 5.2) 1371 0.5 (−1.3 to 2.3)
  Parietal 655 6.4 (3.9 to 9.1) 801 −1.3 (−3.7 to 1.1) 816 −0.4 (−2.7 to 2)
  Other locations 605 5.1 (2.5 to 7.8) 778 0.5 (−1.9 to 3) 989 −1.7 (−3.8 to 0.3)
  Overlapping 298 3.5 (−0.1 to 7.3) 296 −8.8 (−12.5 to 5) 374 −2.3 (−5.6 to 1.1)
  Unspecified 1257 −10.8 (−12.4 to 9.2) 788 −2.9 (−5.2 to 0.4) 727 −10.5 (−12.7 to 8.2)
APC, annual percentage change.
Table 3 Observed age-standardised brain tumour incidence trends in adults (both genders, 20–59 years old) after 
redistribution of unclassified tumours
1982–1992 1993–2002 2003–2013
N APC 95% CI N APC 95% CI N APC 95% CI
All 4793 0.1 (−0.8 to 1) 5270 0.5 (−0.5 to 1.5) 6762 −0.8 (−1.6 to 0)
Histology
  Glioma 4623 0.2 (−0.7 to 1.2) 5094 0.5 (−0.5 to 1.5) 6547 −0.7 (−1.5 to 0.1)
  Glioblastoma 1746 0.4 (−1.1 to 1.9) 2445 2.4 (0.9 to 3.8) 3353 0.7 (−0.5 to 1.9)
  Other glioma 2886 0.1 (−1 to 1.2) 2649 −1.1 (−2.5 to 0.2) 3195 −1.9 (−3 to 0.8)
  Meningioma 84 −1.6 (−7.9 to 5.2) 110 2.4 (−4.2 to 9.4) 120 −4.4 (−10.1 to 1.7)
  Other 82 −8.6 (−14.7 to 2) 66 −1.5 (−9.5 to 7.2) 94 −5.3 (−11.3 to 1)
Glioma grade
  Low 2107 −0.2 (−1.5 to 1.2) 1548 −3.6 (−5.3 to 1.9) 1659 −2.8 (−4.3 to 1.3)
  High 2240 2.4 (1.1 to 3.7) 3442 2.3 (1.1 to 3.5) 4762 0.2 (−0.7 to 1.2)
Glioma topography
  Frontal 1447 1.8 (0.2 to 3.5) 1719 2.3 (0.6 to 4) 2580 1.6 (0.3 to 2.9)
  Temporal 929 1.8 (−0.2 to 3.9) 1252 1.5 (−0.5 to 3.5) 1656 −1.2 (−2.8 to 0.4)
  Parietal 803 3.4 (1.2 to 5.7) 894 –2 (−4.2 to 0.3) 880 −1.1 (−3.3 to 1.1)
  Other locations 948 −0.5 (−2.5 to 1.5) 996 −0.8 (−3 to 1.4) 1198 −3.3 (−5.1 to 1.4)
APC, annual percentage change.
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population-based cancer registration system. Registration 
is mandatory and histological verification rates exceed 
85%.14 In our study, which focused on the age group 
most likely to be affected by mobile phone use, there 
was an increasing trend for glioblastoma when looking 
at the entire observation period (1982–20130). However, 
when looking at different time periods, there was no 
increase in the glioblastoma rates during the period of 
substantial mobile phone use but there was an increase 
in the glioblastoma rates in the earlier periods: 1982–
1992 (non-statistically significant increase), which saw 
increased use of CT and MRI, and 1993–2002 (statistically 
significant increase) which saw further advances in MRI. 
Technological developments in MRI during 1993–2002, 
including diffusion and perfusion imaging, improved 
significantly the discrimination of brain tumour types 
and subtypes.17 23 Other factors, such as improved access 
to care and an increase in the number of specialists, may 
also have played a role in the increase.9 Earlier studies 
investigating trends in brain tumour subtypes including 
glioblastoma have commented that increases in certain 
subtypes are accompanied by decreases in other subtypes 
while overall brain tumour incidence has remained 
stable.24 25 These studies suggest improvements in diag-
nostic technology as the reason for increasing trends in 
certain brain tumour subtypes.24 25
Figure 3 Observed (smoothed*) and predicted (10-year latency) incidence rates in adults (both genders, 20–59 years old) 
during 1982–2013. RR, relative risk.









pen: first published as 10.1136/bm






9Karipidis K, et al. BMJ Open 2018;8:e024489. doi:10.1136/bmjopen-2018-024489
Open access
The results on histology are consistent with the results by 
grade, as high-grade glioma is approximately equivalent 
to glioblastoma. During the period of advances in MRI, 
there was an increase for high-grade lesions and a decrease 
for low-grade, both which levelled off during the period 
of substantial mobile phone use. These results are consis-
tent with incidence trends reported by Barchana et al26 for 
low-grade and high-grade gliomas in Israel between 1980 
and 2009.26 Furthermore, there was a strong decrease for 
unspecified histology and for unspecified grade during 
the first period, and this is likely due to improvements 
in diagnosis using CT and histopathological classifica-
tion.27 There have also been shifts in classifying subtypes 
and grade in updated editions of WHO classification; for 
example, WHO 2000 classification induced a shift from 
anaplastic astrocytoma to glioblastoma.
The results on anatomical location showed that there 
was an increase in gliomas located in the temporal and 
parietal lobes prior to the period of substantial mobile 
phone use, but not during it. There were increases for 
gliomas located in the frontal lobe both before and during 
increased mobile phone use, however, the temporal and 
parietal lobes are more highly exposed to RF radiation 
than other brain sites when using mobile phones. Cardis 
et al1 reported that depending on the type of mobile 
phone and the manner in which it is used, the RF energy 
absorption is at least several times higher in the temporal 
lobe than in the frontal lobe.1 In our data there was a 
large number of gliomas with unspecified or overlapping 
location. Reclassification of these did reduce the trends 
for the temporal lobe during the periods before substan-
tial mobile phone use, and for the frontal lobe during all 
the periods.
In our study, we also compared the observed incidence 
with a modelled predicted incidence assuming a causal 
association between mobile phone use and glioma as 
reported in the Interphone and Hardell studies. The 
results suggest that, if the effects of mobile phones on 
glioma risk are real, then the incidence rates would be 
far higher than those observed. We modelled predicted 
incidence rates for a variety of latency periods up to 20 
years whereas previous studies only included latencies up 
to 10 years.12 13 Previous studies by Little et al13 and more 
recently by Chapman et al14 have also shown that when 
modelling the RRs from the Interphone and Hardell 
studies and assuming a latency of 10 years, the predicted 
incidence rates are much higher.13 14 The exact causes of 
brain cancer are unknown and so is the latency period for 
the disease. Ionising radiation has been shown to induce 
brain cancer by causing DNA damage with a latency 
period of about 5 or more years.28 RF exposure is non-ion-
ising radiation which does not cause direct DNA damage 
and it has been argued that a possible effect would have 
a latency shorter than 5 years.13 However, it has also been 
argued that the latency for an increased risk of brain 
cancer could be both short and long, indicating tumour 
initiation and promotion, respectively.29 In our study, 
we modelled predicted incidence rates for a variety of 
latency periods up to 20 years. Our model found that the 
predicted incidence rates were higher than the observed 
rates for a latency period up to 15 years. A longer observa-
tion period is required in order to model longer latency 
periods.
The present study has some limitations. The accuracy 
of the Australian cancer registration system in the early 
periods when it began in the 80s is unknown for all the 
states and territories. In Northern Territory mandatory 
notification of cancer cases by pathology laboratories was 
introduced in 1991. Case ascertainment was found to be 
approximately 40% incomplete for the period 1981–1986 
and approximately 10% incomplete for the period 1987–
1990. However, the Northern Territory makes up a very 
small proportion of Australia’s population (~1%).30 All 
Australian state and territory registries conform to the 
IARC’s criteria for population-based cancer registration, 
are ‘A’ rated and have their data published in the ‘Cancer 
Incidence in Five Continents’ series.14 31
We estimated mobile phone use using information 
on mobile phone accounts, and this may not be a true 
indicator of actual use as some people may have multiple 
accounts and others may use a phone without having 
an account. We mitigated this by also using data from a 
consumer survey conducted by the national telecommu-
nications regulator on the proportion of the population 
using mobile phones. Information from the survey was 
only available from the years 2009 to 2013 and this was 
applied to data on the annual number of mobile phone 
accounts from 1987. However, mobile phone use patterns 
have likely changed from 1987 to 2009. Further, the expo-
sure metric is unclear when investigating whether mobile 
phone use is implicated in brain cancer risk. Prevalence 
of phone use is a de facto measure for the amount of RF 
energy a person is receiving when using a mobile phone, 
and changes in technology and patterns of individual 
use were not taken into account in this investigation. For 
example, advances in mobile telephony have resulted 
in greatly reduced output power of the phones and the 
evolving use of mobile phones has resulted in less actual 
calling time with the phone against the head.
We estimated the prevalence of mobile phone use 
equally across the 20–59 age range and both males and 
females. The use of subscription data in early years is 
likely to underestimate prevalence of use in males and 
overestimate it in females given that users in early years 
were middle-aged working men on company mobile 
phone subscriptions.14 In later years mobile phone use 
became equal between the two genders.32
For information on the proportion of regular and heavy 
mobile phone users, we used data from the Interphone 
study, which also included data from Australia. Mobile 
phone use in the Interphone study was self-reported, 
relying on participants’ recall of past phone use.3 Sensi-
tivity analyses on the Interphone methodology reported 
that for short term recall (up to a year) there was under-
estimation of phone use by regular users and overestima-
tion by heavy users.33 For longer recall (3–5 years), there 
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was an underestimation of number of calls and an over-
estimation on the duration of calls for all users.34 Based 
on these findings, it is likely that the proportion of heavy 
users in our study is overestimated. Further, the real 
patterns of mobile phone use may be more complex than 
the scenarios we modelled.
Finally this is an ecological observational study, not 
based on individual data, thus, it is not possible to 
account for confounding factors. This study design is 
appropriate to define global trends. The results of our 
study are prone to the ecological fallacy and small risks in 
subgroups in the population may not have been detected. 
Further, the stable trend in brain tumour incidence could 
have concealed a true increasing risk related to mobile 
phone use which appeared flat due to declines in other 
risk factors.
In conclusion, we found no evidence that mobile 
phone use increased any brain tumour histological types 
or subtypes. There was an increase in the incidence of 
glioblastoma prior to the rapid increase in mobile phone 
use which was most likely due to improved diagnosis from 
MRI. Furthermore, there was no increase in gliomas of 
the temporal lobe, which is the most exposed location, 
during the period of substantial mobile phone use. The 
increase in gliomas of the temporal lobe and decrease 
in gliomas of unspecified location during the periods 
prior to substantial mobile phone use are in line with the 
theory of improved diagnosis from CT and MRI. Further, 
the predicted rates were higher than the observed rates 
for latency periods up to 15 years. These results do not 
support an association between mobile phone use and 
brain tumour, although the possibility of a small risk or a 
latency period of more than 15 years cannot be excluded. 
Future research should continue to investigate trends in 
brain tumour histological types, grading and anatom-
ical location for a possible increase with a longer latency 
period.
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